Orexo gains FDA's blessing for sublingual tablet; Purdue nanoparticles designed to react to tumor cell acidity;

> Orexo gained FDA approval for Zubsolv, a once-daily sublingual tablet designed to treat opioid dependence and dissolve quickly. Item

> Eisai says it has come up with a new "dry syrup" formulation using the artificial sweetener sucralose to help boost the likelihood that Alzheimer's patients will take their pills. Story

> Milestone Scientific and Tri-anim Health Services will partner to develop and market injection drug-delivery technology for epidural use during childbirth and other pain management treatments. Item

> Purdue University scientists believe they can deliver cancer drugs more effectively by relying on nanoparticles that both concentrate and expand when in contact with tumor cells' higher acidity. Release

> Catalent has created a new business unit--Advanced Delivery Technologies--that will focus on working with existing and new drug delivery technologies in the development process. Story

> Alliqua raised $3 million through a stock offering in the second quarter of 2013 to help expand its wound dressing portfolio and propel development of its transdermal drug delivery platform. Item